Drug Profile

CTX 340

Alternative Names: CTX-340

Latest Information Update: 18 Feb 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator CRISPR Therapeutics
Class Antihypertensives; Gene therapies
Mechanism of Action Angiotensinogen expression inhibitors; Gene expression modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Preclinical Hypertension

Most Recent Events

13 Feb 2026 CRISPR Therapeutics plans clinical trials in Hypertension in the first half of 2026
10 Nov 2025 Adverse events and pharmacodynamics data from a Preclinical trials in Hypertension released by CRISPR Therapeutics
08 Nov 2025 Pharmacodynamics and adverse event data from a preclinical trial in Hypertension presented at the American Heart Association Scientific Sessions 2025 (AHA-2025)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com